Effect of the excipient concentration on the pharmacokinetics of PM181104, a novel antimicrobial thiazolyl cyclic peptide antibiotic, following intravenous administration to mice

Results in Pharma Sciences

Volumn 4, Issue , 2014, Pages 34-41

  Yemparala, Vijayaphanikumar ^a   Damre, Anagha A ^a   Manohar, Venkat ^a   Singh, Kishori Sharan ^a   Mahajan, Girish B ^a   Sawant, Satish N ^a   Deokule, Tanaji ^a   Sivaramakrishnan, H ^a  

^a Piramal Enterprises Limited   (India)

Author keywords

Antisolvent precipitation; Nanoparticle size; PEG 400; PEG 400 (PubChem CID:657096); Pharmacokinetics; PM181104; Tween 80; Tween 80 (PubChem CID:5281955)

Indexed keywords

EXCIPIENT; MACROGOL 400; PM 181104; POLYPEPTIDE ANTIBIOTIC AGENT; POLYSORBATE 80; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; DRUG FORMULATION; DRUG HALF LIFE; MALE; MOUSE; NONHUMAN; OSMOLARITY; PARTICLE SIZE; PH; STOICHIOMETRY; ZETA POTENTIAL;

EID: 84907511792     PISSN: None     EISSN: 22112863     Source Type: Journal    
DOI: 10.1016/j.rinphs.2014.09.001     Document Type: Article

References (36)

1. Just-Baringo X.J., Albericio F., Álvarez M. Thiopeptide antibiotics: retrospective and recent advances. Mar Drugs 2014, 12:317-351. http://www.ncbi.nlm.nih.gov/pubmed/24445304, 10.3390/md12010317.
2. Martín J., da S Sousa T., Crespo G., Palomo S., González I., Tormo J.R., de la Cruz M., Anderson M., Hill R.T., Vicente F., Genilloud O., Reyes F. Kocurin, the true structure of PM181104, an anti-methicillin-resistant Staphylococcus aureus (MRSA) thiazolyl peptide from the marine-derived bacterium Kocuria palustris. Mar Drugs 2013, 11:387-398. http://www.ncbi.nlm.nih.gov/pubmed/23380989, 10.3390/md11020387.
3. Pucci M.J., Bronson J.J., Barrett J.F., DenBleyker K.L., Discotto L.F., Fung-Tomc J.C., Ueda Y. Antimicrobial evaluation of nocathiacins, a thiazole peptide class of antibiotics. Antimicrob Agents Chemother 2004, 48:3697-3701. http://www.ncbi.nlm.nih.gov/pubmed/15388422, 10.1128/AAC.48.10.3697-3701.2004.
4. Young T.S., Walsh C.T. Identification of the thiazolyl peptide GE37468 gene cluster from Streptomyces ATCC 55365 and heterologous expression in Streptomyces lividans. Proc Natl Acad Sci USA 2011, 108:13053-13058. http://www.ncbi.nlm.nih.gov/pubmed/21788474, 10.1073/pnas.1110435108.
5. Mahajan G., Thomas B., Parab R., Patel Z.E., Kuldharan S., Yemparala V., Mishra P.D., Ranadive P., D'Souza L., Pari K., Sivaramkrishnan H. In vitro and in vivo activities of antibiotic PM181104. Antimicrob Agents Chemother 2013, 57:5315-5319. http://www.ncbi.nlm.nih.gov/pubmed/23939903, 10.1128/AAC.01059-13.
6. Mahajan G.B., George S.D., Ranadive P.V., Mishra P.D.S., Eyyammadichiyil S.S., Panshikar R.M., Sawant S.N., Krishna S., Sivakumar M., Pari K., Thomas B.M., Patel Z.E., Vishwakarma R., Naik C.G., D'Souza L., Prabha D. Novel Antibact Compds 2009. US Patent 2009/0076094 A1.
7. Just-Baringo X., Bruno P., Ottesen L.K., Cañedo L.M., Albericio F., Álvarez M. Total synthesis and stereochemical assignment of baringolin. Angew Chem (Int Ed. Engl) 2013, 52(30):7818-7821. http://www.ncbi.nlm.nih.gov/pubmed/23780649, 10.1002/anie.201302372.
8. Strickley R.G. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004, 21:201-230. http://www.ncbi.nlm.nih.gov/pubmed/15032302, 10.1023/B:PHAM.0000016235.32639.23.
9. Chari K., Antalek B., Kowalczyk J., Eachus R.S., Chen T. Polymer-surfactant interaction and stability of amorphous colloidal particles. J Phys Chem B 1999, 103:9867-9872. 10.1021/jp992032i.
10. Hao L., Wang X., Zhang D., Xu Q., Song S., Wang F., Li C., Guo H., Liu Y., Zheng D., Zhang Q. Studies on the preparation, characterization and pharmacokinetics of Amoitone B nanocrystals. Int J Pharm 2012, 433:157-164. http://www.ncbi.nlm.nih.gov/pubmed/22579996, 10.1016/j.ijpharm.2012.05.002.
11. Kovács K., Antal I., Stampf G., Klebovich I., Ludányi K. Composition optimization and stability testing of a parenteral antifungal solution based on a ternary solvent system. AAPS PharmSciTech 2010, 11:285-293. http://www.ncbi.nlm.nih.gov/pubmed/20182828, 10.1208/s12249-009-9368-1.
12. Dong Y., Ng W.K., Shen S., Kim S., Tan R.B.H. Preparation and characterization of spironolactone nanoparticles by antisolvent precipitation. Int J Pharm 2009, 375:84-88. http://www.ncbi.nlm.nih.gov/pubmed/19481693, 10.1016/j.ijpharm.2009.03.013.
13. Wacker M. Nanocarriers for intravenous injection-the long hard road to the market. Int J Pharm 2013, 457:50-62. http://www.ncbi.nlm.nih.gov/pubmed/24036012, 10.1016/j.ijpharm.2013.08.079.
14. Yalkowsky S.H., Krzyzaniak J.F., Ward G.H. Formulation-related problems associated with intravenous drug delivery. J Pharm Sci 1998, 87:787-796. http://www.ncbi.nlm.nih.gov/pubmed/9649344, 10.1021/js980051i.
15. Gelderblom H., Verweij J., Nooter K., Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001, 37:1590-1598. http://www.ncbi.nlm.nih.gov/pubmed/11527683, 10.1016/S0959-8049(01)00171-X.
16. Chen H., Zhang Z., McNulty C., Olbert C., Yoon H.J., Lee J.W., Kim S.C., Seo M.H., Oh H.S., Lemmo A.V., Ellis S.J., Heimlich K. A high-throughput combinatorial approach for the discovery of a cremophor EL-free paclitaxel formulation. Pharm Res 2003, 20:1302-1308. http://www.ncbi.nlm.nih.gov/pubmed/12948029, 10.1023/A:1025021603288.
17. Ali M.E., Lamprecht A. Polyethylene glycol as an alternative polymer solvent for nanoparticle preparation. Int J Pharm 2013, 456:135-142. http://www.ncbi.nlm.nih.gov/pubmed/23958752, 10.1016/j.ijpharm.2013.07.077.
18. Webster R., Elliott V., Park B.K., Walker D., Hankin M., Taupin P. PEG and PEG conjugates toxicity: Towards an understanding of the toxicity of PEG and its relevance to pegylated BioLogicals. Pegylated protein drugs: Basic science and clinical applications 2009, 127-146. Birkhauser, Basel, Switzerland. F.M. Veronese (Ed.).
19. Joshi M., Pathak S., Sharma S., Patravale V. Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: nanoject. Int J Pharm 2008, 364:119-126. http://www.ncbi.nlm.nih.gov/pubmed/18765274, 10.1016/j.ijpharm.2008.07.032.
20. van Tellingen O., Beijnen J.H., Verweij J., Scherrenburg E.J., Nooijen W.J., Sparreboom A. Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. Clin Cancer Res 1999, 5:2918-2924. http://www.ncbi.nlm.nih.gov/pubmed/10537361.
21. Matteucci M.E., Hotze M.A., Johnston K.P., Williams R.O. Drug nanoparticles by antisolvent precipitation: mixing energy versus surfactant stabilization. Langmuir 2006, 22:8951-8959. http://www.ncbi.nlm.nih.gov/pubmed/17014140, 10.1021/la061122t.
22. Tang X.J., Fu Y.H., Meng Q.H., Li L.M., Ying X.Y., Han M., He Q.J., Yang B., Zeng S., Hu Y.Z., Sheng X.X., Gao J.Q. Evaluation of pluronic nanosuspensions loading a novel insoluble anticancer drug both in vitro and in vivo. Int J Pharm 2013, 456:243-250. http://www.ncbi.nlm.nih.gov/pubmed/23928148, 10.1016/j.ijpharm.2013.07.058.
23. Pardeike J., Weber S., Haber T., Wagner J., Zarfl H.P., Plank H., Zimmer A. Development of an itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application. Int J Pharm 2011, 419:329-338. http://www.ncbi.nlm.nih.gov/pubmed/21839157, 10.1016/j.ijpharm.2011.07.040.
24. Patel M.R., Linna T.J. Enrichment of mouse splenic natural killer cells using discontinuous polyvinylpyrrolidone silica (Percoll) gradients. Immunology 1984, 53:721-729. http://www.ncbi.nlm.nih.gov/pubmed/6094339.
25. Doellman D., Hadaway L., Bowe-Geddes L.A., Franklin M., LeDonne J., Papke-O'Donnell L., Pettit J., Schulmeister L., Stranz M. Infiltration and extravasation: update on prevention and management. J Infus Nurs 2009, 32:203-211. http://www.ncbi.nlm.nih.gov/pubmed/19605999, 10.1097/NAN.0b013e3181aac042.
26. Owens D.E., Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006, 307:93-102. http://www.ncbi.nlm.nih.gov/pubmed/16303268, 10.1016/j.ijpharm.2005.10.010.
27. Cedervall T., Lynch I., Lindman S., Berggård T., Thulin E., Nilsson H., Dawson K.A., Linse S. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci USA 2007, 104:2050-2055. http://www.ncbi.nlm.nih.gov/pubmed/17267609, 10.1073/pnas.0608582104.
28. Lundqvist M., Stigler J., Elia G., Lynch I., Cedervall T., Dawson K.A. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci USA 2008, 105:14265-14270. http://www.ncbi.nlm.nih.gov/pubmed/18809927, 10.1073/pnas.0805135105.
29. Vonarbourg A., Passirani C., Saulnier P., Benoit J.P. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 2006, 27:4356-4373. http://www.ncbi.nlm.nih.gov/pubmed/16650890, 10.1016/j.biomaterials.2006.03.039.
30. Pratten M.K., Lloyd J.B. Pinocytosis and phagocytosis: the effect of size of a particulate substrate on its mode of capture by rat peritoneal macrophages cultured in vitro. Biochim Biophys Acta 1986, 881:307-313. http://www.ncbi.nlm.nih.gov/pubmed/3008849, 10.1016/0304-4165(86)90020-6.
31. Wong J., Brugger A., Khare A., Chaubal M., Papadopoulos P., Rabinow B., Kipp J., Ning J. Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv Drug Deliv Rev 2008, 60:939-954. 10.1016/j.addr.2007.11.008.
32. Araujo L., Löbenberg R., Kreuter J. Influence of the surfactant concentration on the body distribution of nanoparticles. J Drug Target 1999, 6:373-385. http://www.ncbi.nlm.nih.gov/pubmed/10342385, 10.3109/10611869908996844.
33. Loos W.J., Baker S.D., Verweij J., Boonstra J.G., Sparreboom A. Clinical pharmacokinetics of unbound docetaxel: Role of polysorbate 80 and serum proteins. Clin Pharmacol Ther 2003, 74:364-371. http://www.ncbi.nlm.nih.gov/pubmed/14534523, 10.1016/S0009-9236(03)00222-4.
34. Dobrovolskaia M.A., McNeil S.E. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007, 2:469-478. http://www.ncbi.nlm.nih.gov/pubmed/18654343, 10.1038/nnano.2007.223.
35. Gao L., Zhang D., Chen M., Duan C., Dai W., Jia L., Zhao W. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int J Pharm 2008, 355:321-327. http://www.ncbi.nlm.nih.gov/pubmed/18242896, 10.1016/j.ijpharm.2007.12.016.
36. FDA/Center for Drug Evaluation and Research, Office of Generic Drugs. Inactive Ingredient Search for Approved Drug Products; October 24, 2013. [Available from:]. http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm.